Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization

Fertility and Sterility

Volumn 80, Issue 1, 2003, Pages 103-110

  Posada, M Natalia ^a,b   Vlahos, Nikos P ^a   Jurema, Marcus W ^a   Bracero, Nabal J ^a   Wallach, Edward E ^a   Garcia, Jairo E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Instituto Antioqueno de Reproduccion   (Colombia)

Author keywords

Controlled ovarian stimulation; Flare up protocol; Ganirelix acetate; In vitro fertilization; Leuprolide acetate

Indexed keywords

CHORIONIC GONADOTROPIN; GANIRELIX; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMAN; HYPOPHYSIS; MAJOR CLINICAL STUDY; NIDATION; OOCYTE DEVELOPMENT; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0038383560     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)00500-4     Document Type: Article

References (39)

1. Hughes E., Fedorkow D., Daya S., Sagle M., Van de Koppel P., Collins J. The routine use of gonadotropin releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer a meta-analysis of randomized controlled trials . Fertil Steril. 58:1992;888-896.
2. Hughes J., Durnerin I. Revisiting gonadotropin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotropins. Hum Reprod Update. 64:1998;83-101.
3. Macnamee M.C., Howles C.M., Edwards R.G. Pregnancies after IVF when tonic LH is reduced by long-term treatment with GnRH agonists. Hum Reprod. 2:1987;569-571.
4. Howles C.M., Macnamee M.C., Edwards R.G. Short-term use of a LHRH agonist to treat poor responders entering an in vitro fertilization (IVF) programme. Hum Reprod. 2:1987;17-21.
5. Surrey E.S., Schoolcraft W.B. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril. 73:2000;667-676.
6. Macnamee M.C., Howles C.M., Edwards R.G., Taylor P.J., Elder K.T. Short term luteinizing hormone-releasing hormone agonist treatment prospective trial of a novel ovarian stimulation regimen for in vitro fertilization . Fertil Steril. 52:1989;264-269.
7. Winslow K.L., Toner J.P., Brzyski R.G., Oehninger S.C., Acosta A.A., Muasher S.J. The gonadotropin-releasing hormone agonist stimulation test agonists sensitive predictor of performance in the flare-up in vitro fertilization cycle. Fertil Steril. 56:1991;711-717.
8. Padilla S.L., Bayati J., Garcia J.E. Prognostic value of the early serum estradiol response to leuprolide acetate in vitro fertilization. Fertil Steril. 53:1990;288-294.
9. Padilla S.L., Smith R.D., Garcia J.E. The Lupron screening test tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization . Fertil Steril. 56:1991;79-83.
10. Scott R.T., Hofmann G.E. Prognostic assessment of ovarian reserve. Fertil Steril. 63:1995;1-11.
11. Scott R.T., Toner J.P., Muasher S.J., Oehninger S., Robinson S., Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril. 51:1989;650-654.
12. Ranieri D.M., Quinn F., Makhlouf A., Khadum I., Ghutmi W., McGarrigie H., et al. Simultaneous evaluation of basal follicle-stimulating hormone and 17beta-estradiol response to gonadotropin-releasing hormone analogue stimulation an improved predictor of ovarian reserve . Fertil Steril. 70:1998;227-233.
13. Padilla S.L., Garcia J.E. Effect of maternal age and number of in vitro fertilization procedures on pregnancy outcome. Fertil Steril. 52:1989;270-273.
14. Padilla S.L., Dugan K., Maruschak V., Shalika S., Smith R.D. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril. 65:1996;796-799.
15. Karande V., Morris R., Rinehart J., Miller C., Rao R., Gleicher N. Limited success using the "flare" protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization. Fertil Steril. 67:1997;900-903.
16. Navot D., Rosenwaks Z., Anderson F., Hodgen G.D. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation low-dose side effects in women and monkeys . Fertil Steril. 55:1991;1069-1075.
17. Scott R.T., Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril. 61:1994;880-885.
18. Schoolcraft W., Schlenker T., Gee M., Stevens J., Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril. 67:1997;93-97.
19. Surrey E.S., Bower J., Hill D.M., Ramsey J., Surrey M.W. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril. 69:1998;419-424.
20. Beckers N.G., Laven J.S., Eijkemans M.J., Fauser B.C. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization. Hum Reprod. 15:2000;43-49.
21. Donderwinkel P.F., Schoot D.C., Pache T.D., de Jong F.H., Hop W.C., Fauser B.C. Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist. Hum Reprod. 8:1993;2027-2032.
22. Sungurtekin U., Jansen R.P. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril. 63:1995;663-665.
23. San Roman G.A., Surrey E.S., Judd H.L., Kerin J.F. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril. 58:1992;744-749.
24. Garcia JE, Padilla SL, Bayati J, Baramki TA. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. 1990;53:302-5.
25. Gelety T.J., Pearlstone A.C., Surrey E.S. Short term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women. Fertil Steril. 64:1995;1074-1080.
26. Bo-Abbas Y.Y., Martin K.A., Liberman R.F., Cramer D.W., Barbieri R.L. Serum and follicular fluid hormone levels during in vitro fertilization after short- or long-course treatment with a gonadotropin-releasing hormone agonist. Fertil Steril. 75:2001;694-699.
27. Felberbaum R., Diedrich K. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues agonists and antagonists . Hum Reprod. 14:1999;207-221.
28. Albano C., Smitz J., Tournaye H., Riethmuller-Winzen H., Van Steirteghem A., Devroey P. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Hum Reprod. 14:1999;1426-1430.
29. Duijkers I.J., Klipping C., Willemsen W.N., Krone D., Schneider E., Niebch G., et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod. 13:1998;2392-2398.
30. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 13:1998;3023-3031.
31. De Jong D., Macklon N.S., Eijkemans M.J., Mannaerts B.M., Coelingh Bennink H.J., Fauser B.C. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertil Steril. 75:2001;688-693.
32. Olivennes F., Alvarez S., Bouchard P., Fanchini R., Salat-Baroux J., Frydman R. The use of GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer a dose finding study of 3 versus 2 mg . Hum Reprod. 13:1998;2411-2414.
33. Fluker M., Grifo J., Leader A., Levy M., Meldrum D., Muasher S.J., et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. The North American Ganirelix Study Group. Fertil Steril. 75:2001;38-45.
34. Comparable clinical outcome using the GnRh antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 16:2001;644-651.
35. Albano C., Felberbaum R.E., Smitz J., Riethmuller-Winzen H., Engel J., Diedrich K., et al. Ovarian stimulation with HMG results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist Cetrorelix and the LHRH-agonist buserelin . Hum Reprod. 15:2000;526-531.
36. Olivennes F., Mannaerts B., Struijs M., Bonduelle M., Devroey P. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI a preliminary report . Hum Reprod. 16:2001;1588-1591.
37. Ludwig M., Riethmuller-Winzen H., Felberbaum R.E., Olivennes F., Albano C., Devroey P., et al. Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrolix. Fertil Steril. 75:2001;18-22.
38. Akman M.A., Erden H.F., Tosun S.B., Bayazit N., Aksoy E., Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders results of a prospective randomized trial . Hum Reprod. 6:2001;868-870.
39. Diggle P.J., Liang K.Y., Zeger S.L. Analysis of longitudinal data. 1994;Clarendon Press, Oxford, UK.